Should I Buy KMTS? KMTS 2026 Analysis

Should You Buy Kestra Medical Technologies Ltd (KMTS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

25.470

1 Day change

1.39%

52 Week Range

30.000

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price ($25.58 pre-market) is pressing into near-term resistance (R1 $25.84) without any proprietary buy signal.
Technicals are bullish, but the setup is more “chasing strength near resistance” than a clean risk/reward entry.
Wall Street is constructive overall, yet the most recent notable update is Goldman’s target cut to $24 (below the current price), which caps near-term upside expectations.
Fundamentals show strong growth and margin expansion, but the company is still deeply loss-making, which can keep the stock choppy without a fresh catalyst.
No recent news catalyst and no notable insider/hedge/congress activity to suggest an imminent momentum trigger.

Technical Analysis

Trend/MAs: Bullish structure with SMA_5 > SMA_20 > SMA_200, consistent with an uptrend.
Momentum: MACD histogram positive (0.205) and expanding, supporting continued upside momentum.
RSI: RSI_6 at ~65.9 (neutral-to-warm), not overbought but getting closer to stretched territory.
Key levels: Pivot $24.90; resistance R1 $25.84 then R2 $26.42; support S1 $23.96. At $25.58 the stock is closer to resistance than support, worsening near-term risk/reward for a new buy.
Pattern-based forward look (similar candlesticks): modest 1-week upside (+2.4%) but negative 1-month bias (-5.3%), implying risk of a pullback after near-term strength.
Intellectia Proprietary Trading Signals: No signal on given stock today (AI Stock Picker: none; SwingMax: none).

Positive Catalysts

- Strong underlying business momentum: FY/Q2 showed 53% YoY revenue growth with major gross margin expansion (~50.6%).
- Multiple bullish/positive analyst stances (Piper, Wells Fargo, Stifel, BTIG) citing share gains and improving profitability trajectory.
- Bullish technical trend (moving averages + MACD) can continue to attract momentum buyers if $25.84/$26.42 break.
- Trading flows: insiders and hedge funds are neutral (no negative flow pressure signaled).

Neutral/Negative Catalysts

- No near-term news/events in the past week to act as an immediate upside catalyst.
- Most recent high-profile change: Goldman Sachs cut its price target to $24 (below current), signaling limited upside in the near term from that camp.
- Despite growth, profitability is still meaningfully negative (large net loss), which can trigger pullbacks if growth expectations cool.
- Price is currently close to resistance (R1), increasing the odds of a near-term stall/rejection for an impatient entry.
- Congress/politician activity: no recent congress trading data available (no supportive signal from influential buyers).

Financial Performance

Latest reported quarter: 2026/Q2.
Revenue: $22.565M, +53.40% YoY (strong top-line growth).
Gross margin: 50.63%, +27.76% YoY (major margin expansion, positive operating leverage signal).
Net income: -$32.785M (still deeply negative), though improved +38.39% YoY.
EPS: -$0.64, improved +33.33% YoY (loss narrowing but not yet profitable).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Generally positive coverage and rising targets into mid-December after strong Q2 and raised guidance; however, Goldman’s view remains Neutral and its target was recently cut.
Latest changes:
- 2026-01-16 Goldman Sachs: Neutral, PT cut to $24 from $27 (bearish relative to current price).
- 2026-01-09 Goldman Sachs: Neutral, PT raised to $27 from $25 (prior optimism, later reversed).
- 2025-12-12 Piper Sandler: Overweight, PT $30 (bullish; encouraged buying).
- 2025-12-12 Wells Fargo: Overweight, PT $28 (bullish).
- 2025-12-12 Stifel: Buy, PT $30 (bullish).
- 2025-11-18 BTIG: Buy, PT $32 (bullish initiation).
Wall Street pros vs cons:
- Pros: Strong growth, expanding margins, share gains narrative, repeated “beat-and-raise” expectation (multiple Buy/Overweight).
- Cons: Neutral camp (Goldman) is not endorsing upside at current levels; stock can be sensitive given ongoing losses and the lack of a fresh catalyst.

6 Analyst Rating

Wall Street analysts forecast KMTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMTS is 29.5 USD with a low forecast of 27 USD and a high forecast of 32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 25.120

Low

Averages

29.5

High

Current: 25.120

Low

Averages

29.5

High

Goldman Sachs

Neutral

downgrade

$27 -> $24

AI Analysis

2026-01-16

Reason

Goldman Sachs

Price Target

$27 -> $24

AI Analysis

2026-01-16

downgrade

Neutral

Reason

Goldman Sachs lowered the firm's price target on Kestra Medical to $24 from $27 and keeps a Neutral rating on the shares. MedTech and Healthcare IT stocks fell sharply from January 8-14, declining about 3% and 11%, respectively, in a move that appears largely disconnected from fundamentals, the analyst tells investors in a research note. Even companies pre-announcing above-consensus results saw share weakness, despite forward outlooks generally at or above current Street expectations, the firm says.

Goldman Sachs

Neutral

maintain

$25 -> $27

2026-01-09

Reason

Goldman Sachs

Price Target

$25 -> $27

2026-01-09

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Kestra Medical to $27 from $25 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KMTS

Unlock Now

KMTS Should I Buy

KMTS Should I Buy

Should You Buy Kestra Medical Technologies Ltd (KMTS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch